Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis

Meizhen Xu; Yina Liu; Dan Li; Xuelin Wang; Shuang Liang; Gaochuan Zhang; Xiaoqin Yang

doi:10.18632/oncotarget.18981

Chinese C allele carriers of the ERCC5 rs1047768 polymorphism are more sensitive to platinum-based chemotherapy: a meta-analysis

Oncotarget. 2017 Jul 4;9(1):1248-1256. doi: 10.18632/oncotarget.18981. eCollection 2018 Jan 2.

Authors

Meizhen Xu¹, Yina Liu¹, Dan Li^{2

3

4}, Xuelin Wang⁵, Shuang Liang⁶, Gaochuan Zhang¹, Xiaoqin Yang¹

Affiliations

¹ School of Biology and Basic Medical Sciences, Soochow University, Suzhou, China.
² Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
³ School of Life Science and Technology, Tongji University, Shanghai, China.
⁴ Present address: Jiayin BioTechnology Co., Ltd., Shanghai, China.
⁵ Yushan Town, Kunshan, China.
⁶ Scotch Plains, New Jersey, USA.

Abstract

It is suspected that ERCC5 rs1047768 and rs17655 polymorphisms influence the response to platinum-based chemotherapy. This meta-analysis was performed to summarize the scattered evidence regarding the association between these two polymorphisms and sensitivity to platinum-based treatment. Thirteen studies were included after a comprehensive literature search. The pooled odds ratios and 95% confidence intervals suggested that the C allele of the ERCC5 rs1047768 polymorphism is associated with elevated sensitivity to platinating agents, especially for Chinese patients. However, no difference among rs17655 genotypes could be detected.

Keywords: ERCC5; cancer; meta-analysis; platinum-based chemotherapy; polymorphism.